Generics to challenge GSK’s prostate, hair loss drug in Korea
Jan 22, 2016
Local drugmakers have begun a competition to secure their portion of South Korea’s prostatic hyperplasia and hair loss medication market, as the last of GlaxoSmithKline’s Korean patents on Avodart (dutasteride) expired Thursday. Avodart is a drug able to treat both enlarged prostate gland symptoms as well as hair loss. GSK had held a separate patent for each of the drug’s two therapeutic effects, veering off competition. GSK’s local patent on the drug’s ability to treat the former symptom expire